Aminostyrylbenzofuran directly reduces oligomeric amyloid-β and reverses cognitive deficits in Alzheimer transgenic mice

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Lee, Sang Hyun ^a,b   Kim, YoungSoo ^c,d   Kim, Hye Yun ^b,c,d   Kim, Young Hoon ^a   Kim, Maeng Sup ^a   Kong, Jae Yang ^e   Lee, Mun Han ^b   Kim, Dong Jin ^c   Ahn, Young Gil ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

^e Keimyung University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 (4 DIMETHYLAMINOSTYRYL) BENZOFURAN; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; KMS 88009; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG UPTAKE; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; RAT; SINGLE DRUG DOSE; TREATMENT OUTCOME; ANIMAL; CHEMISTRY; COGNITION DISORDERS; DISEASE MODEL; METABOLISM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BENZOFURANS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, TRANSGENIC;

EID: 84899720596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095733     Document Type: Article

References (18)

1. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Bio 8: 101-112. (Pubitemid 46432529)
2. Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, et al. (2010) Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 88: 2923-2932.
3. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, et al. (2007) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28: 537-547. (Pubitemid 46282205)
4. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 73: 504-517.
5. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517.
6. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
7. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ (2012) Immunotherapy for Alzheimer disease-the challenge of adverse effects. Nat Rev Neurol 8: 465-469.
8. Byun JH, Kim H, Kim Y, Mook-Jung I, Kim DJ, et al. (2008) Aminostyrylbenzofuran derivatives as potent inhibitors for A beta fibril formation. Bioorg Med Chem Lett 18: 5591-5593.
9. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282: 36275-36282.
10. Reiserer RS, Harrison FE, Syverud DC, McDonald MP (2007) Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 6: 54-65. (Pubitemid 46090333)
11. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808. (Pubitemid 44050070)
12. Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 94: 491-495. (Pubitemid 18087398)
13. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-683. (Pubitemid 12096189)
14. Fanselow MS (1980) Conditioned and unconditional components of post-shock freezing. Pavlov J Biol Sci 15: 177-182.
15. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204-1222.
16. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
17. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398.
18. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337: 1488-1492.